EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Real-world analysis on hemodynamic effectiveness and adverse events of selexipag in pulmonary arterial hypertension

Ryotaro Asano iD, Takatoyo Kiko, Takanori Kawabata, Yuka Sano, Hiroyuki Endo, Ryo Takano, Shinya Fujisaki, Hiroya Hayashi, Jin Ueda, Akihiro Tsuji, Koichi Matsuoka, Kohji Murakami und 1 weitere

Therapeutic Advances in Respiratory Disease · 2026

DOI: 10.1177/17534666261484754 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2026. Verfasst von Ryotaro Asano und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan. Hauptthemen laut MEDLINE: Acetamides, Pyrazines, Pulmonary Arterial Hypertension, Antihypertensive Agents. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nippon Shinyaku Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Selexipag, an oral IP prostacyclin receptor agonist, improves outcomes in pulmonary arterial hypertension (PAH); however, real-world hemodynamic data and the relationship between adverse events (AEs) and treatment response are limited.

Objectives

The aims of this study were to evaluate the efficacy and safety of selexipag in a Japanese cohort and assess whether treatment-emergent adverse events, particularly headache and diarrhea, were associated with subsequent hemodynamic responses.

Design

We conducted a retrospective observational study at the National Cerebral and Cardiovascular Center in Japan.

Methods

We retrospectively analyzed consecutive patients with PAH initiating selexipag at our institution between 2016 and 2022. Baseline and follow-up right heart catheterization, 6-minute walk distance (6MWD), and B-type natriuretic peptide (BNP) were assessed at 26, 52, and 104 weeks. AEs requiring treatment were recorded.

Results

Of the 97 included patients, 94% received dual or triple PAH therapies at baseline. At 52 weeks, selexipag was associated with reductions in pulmonary vascular resistance (−1.36±4.70 Wood units; p =0.036) and mean pulmonary artery pressure (mPAP; −4.27±9.61 mmHg; p =0.001) and an increase in 6MWD (+26.6±53.8 m; p =0.003), without significant changes in cardiac index or BNP. The proportion of patients at low ESC/ERS 3-strata risk increased from 63% to 78% ( p =0.017). AEs occurred in 62% of patients, most commonly headache (42%) and diarrhea (29%). Headaches, typically developing during dose escalation, might be associated with a better prognosis through greater mPAP reduction.

Conclusion

Selexipag initiation improved pulmonary hemodynamics, exercise capacity, and risk profile, without new safety signals. Headache, a common prostacyclin-related AE, may indicate treatment responsiveness and predict therapeutic outcomes. Careful titration to the maximally tolerated dose with vigilant AE management may optimize outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcetamidesPyrazinesPulmonary Arterial HypertensionAntihypertensive AgentsHemodynamicsHumansRetrospective StudiesFemaleMaleTreatment OutcomeMiddle AgedJapanAgedDiarrheaHeadacheTime FactorsNatriuretic Peptide, BrainVascular ResistanceReceptors, Epoprostenol

Stichwörter der Autor:innen

headachehemodynamicsprostacyclin receptor agonistpulmonary arterial hypertensionselexipag

Substanzen

selexipagAcetamidesPyrazinesAntihypertensive AgentsNatriuretic Peptide, BrainReceptors, Epoprostenol

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
  • Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan.
  • Department of Data Science, National Cerebral and Cardiovascular Center, Osaka, Japan.
  • Medical Affairs, Nippon Shinyaku Co., Ltd., Kyoto, Japan.

ORCID-Profile: Ryotaro Asano

Förderung

  • Nippon Shinyaku Co., Ltd.

Zitieren

APA

Asano, R., Kiko, T., Kawabata, T., Sano, Y., Endo, H., Takano, R., Fujisaki, S., Hayashi, H., Ueda, J., Tsuji, A., Matsuoka, K., Murakami, K., & Ogo, T. (2026). Real-world analysis on hemodynamic effectiveness and adverse events of selexipag in pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666261484754

Vancouver

Asano R, Kiko T, Kawabata T, Sano Y, Endo H, Takano R, et al. Real-world analysis on hemodynamic effectiveness and adverse events of selexipag in pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease. 2026. doi:10.1177/17534666261484754

BibTeX
@article{Asano2026,
  author = {Asano, Ryotaro and Kiko, Takatoyo and Kawabata, Takanori and Sano, Yuka and Endo, Hiroyuki and Takano, Ryo and Fujisaki, Shinya and Hayashi, Hiroya and Ueda, Jin and Tsuji, Akihiro and Matsuoka, Koichi and Murakami, Kohji and Ogo, Takeshi},
  title = {Real-world analysis on hemodynamic effectiveness and adverse events of selexipag in pulmonary arterial hypertension},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2026},
  doi = {10.1177/17534666261484754}
}
Kostenlos starten →